The HOX genes network in uro-genital cancers

Mechanisms and potential therapeutic implications

M. Cantile, R. Franco, G. Schiavo, A. Procino, L. Cindolo, G. Botti, C. Cillo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Genito-urinary malignancies (prostate, bladder, renal and testicular cancers) rank high among human tumors with an incidence that varies with age and organ involvement. Prostate cancer is the most commonly detected male cancer followed by bladder and kidney cancers, less frequent in women. Testicular cancer, although rare, is the most frequent cancer in males under 35. The majority of oncogenic and tumor suppressor signaling pathways involved with urogenital cancers converge on sets of transcription factors that ultimately control gene expression resulting in tumor formation and metastatic progression. The activity of these transcription factors is modulated by multiple mechanisms spanning from transcriptional regulation, deregulation of the splicing, maturation, export and location of mRNAs, protein synthesis and post-translational modifications. The recent involvement of the epigenitic mechanisms in the generation and the evolution of cancer has produced a great deal of interest. This is related to the possibility that revealing these mechanisms able to regulate the cell memory program (the gene systems polycomb, trithorax and HOX) may generate important biological and therapeutic achievements. The HOX gene network is the only physically and functionally identifiable transcription factor network located in the human genome controlling crucial cellular processes. Here we describe the implication of the HOX genes in the urogenital embryonic development and cancers. We further highlight the mechanisms uncovered along these processes and involving the HOX genes. Finally, we foresee the specific targeting of HOX genes and in general the cell memory gene program in the therapeutic setting of urogenital malignancies due to their upstream location in these stepwise cell processes and their early deregulation in cancer evolution.

Original languageEnglish
Pages (from-to)4872-4884
Number of pages13
JournalCurrent Medicinal Chemistry
Volume18
Issue number32
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Gene Regulatory Networks
Genes
Neoplasms
Kidney Neoplasms
Tumors
Transcription Factors
Deregulation
Urinary Bladder Neoplasms
Therapeutics
Testicular Neoplasms
Prostatic Neoplasms
Data storage equipment
Urogenital Neoplasms
Gene expression
Gene Targeting
Human Genome
Post Translational Protein Processing
Computer systems
Embryonic Development
Messenger RNA

Keywords

  • Anti-Epigenetic Drugs
  • Epigenetic therapies
  • Epigenetics and cancer
  • HOTAIR
  • HOTTIP
  • HOX genes
  • HOX genes and cell identity
  • HOX genes and epithelial-mesenchymal interaction
  • HOX genes and miRNA
  • HOX genes and ncRNA
  • HOX genes and uro-genital cancers
  • HOX/PBX and therapy
  • HOXC11 and kidney cancer
  • HOXC4
  • HOXC5 and HOXC6 and bladder cancer
  • HOXC6 and prostate cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

The HOX genes network in uro-genital cancers : Mechanisms and potential therapeutic implications. / Cantile, M.; Franco, R.; Schiavo, G.; Procino, A.; Cindolo, L.; Botti, G.; Cillo, C.

In: Current Medicinal Chemistry, Vol. 18, No. 32, 11.2011, p. 4872-4884.

Research output: Contribution to journalArticle

Cantile, M. ; Franco, R. ; Schiavo, G. ; Procino, A. ; Cindolo, L. ; Botti, G. ; Cillo, C. / The HOX genes network in uro-genital cancers : Mechanisms and potential therapeutic implications. In: Current Medicinal Chemistry. 2011 ; Vol. 18, No. 32. pp. 4872-4884.
@article{66a8264b4edd46af8d9e0dafbc1afb0a,
title = "The HOX genes network in uro-genital cancers: Mechanisms and potential therapeutic implications",
abstract = "Genito-urinary malignancies (prostate, bladder, renal and testicular cancers) rank high among human tumors with an incidence that varies with age and organ involvement. Prostate cancer is the most commonly detected male cancer followed by bladder and kidney cancers, less frequent in women. Testicular cancer, although rare, is the most frequent cancer in males under 35. The majority of oncogenic and tumor suppressor signaling pathways involved with urogenital cancers converge on sets of transcription factors that ultimately control gene expression resulting in tumor formation and metastatic progression. The activity of these transcription factors is modulated by multiple mechanisms spanning from transcriptional regulation, deregulation of the splicing, maturation, export and location of mRNAs, protein synthesis and post-translational modifications. The recent involvement of the epigenitic mechanisms in the generation and the evolution of cancer has produced a great deal of interest. This is related to the possibility that revealing these mechanisms able to regulate the cell memory program (the gene systems polycomb, trithorax and HOX) may generate important biological and therapeutic achievements. The HOX gene network is the only physically and functionally identifiable transcription factor network located in the human genome controlling crucial cellular processes. Here we describe the implication of the HOX genes in the urogenital embryonic development and cancers. We further highlight the mechanisms uncovered along these processes and involving the HOX genes. Finally, we foresee the specific targeting of HOX genes and in general the cell memory gene program in the therapeutic setting of urogenital malignancies due to their upstream location in these stepwise cell processes and their early deregulation in cancer evolution.",
keywords = "Anti-Epigenetic Drugs, Epigenetic therapies, Epigenetics and cancer, HOTAIR, HOTTIP, HOX genes, HOX genes and cell identity, HOX genes and epithelial-mesenchymal interaction, HOX genes and miRNA, HOX genes and ncRNA, HOX genes and uro-genital cancers, HOX/PBX and therapy, HOXC11 and kidney cancer, HOXC4, HOXC5 and HOXC6 and bladder cancer, HOXC6 and prostate cancer",
author = "M. Cantile and R. Franco and G. Schiavo and A. Procino and L. Cindolo and G. Botti and C. Cillo",
year = "2011",
month = "11",
doi = "10.2174/092986711797535182",
language = "English",
volume = "18",
pages = "4872--4884",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "32",

}

TY - JOUR

T1 - The HOX genes network in uro-genital cancers

T2 - Mechanisms and potential therapeutic implications

AU - Cantile, M.

AU - Franco, R.

AU - Schiavo, G.

AU - Procino, A.

AU - Cindolo, L.

AU - Botti, G.

AU - Cillo, C.

PY - 2011/11

Y1 - 2011/11

N2 - Genito-urinary malignancies (prostate, bladder, renal and testicular cancers) rank high among human tumors with an incidence that varies with age and organ involvement. Prostate cancer is the most commonly detected male cancer followed by bladder and kidney cancers, less frequent in women. Testicular cancer, although rare, is the most frequent cancer in males under 35. The majority of oncogenic and tumor suppressor signaling pathways involved with urogenital cancers converge on sets of transcription factors that ultimately control gene expression resulting in tumor formation and metastatic progression. The activity of these transcription factors is modulated by multiple mechanisms spanning from transcriptional regulation, deregulation of the splicing, maturation, export and location of mRNAs, protein synthesis and post-translational modifications. The recent involvement of the epigenitic mechanisms in the generation and the evolution of cancer has produced a great deal of interest. This is related to the possibility that revealing these mechanisms able to regulate the cell memory program (the gene systems polycomb, trithorax and HOX) may generate important biological and therapeutic achievements. The HOX gene network is the only physically and functionally identifiable transcription factor network located in the human genome controlling crucial cellular processes. Here we describe the implication of the HOX genes in the urogenital embryonic development and cancers. We further highlight the mechanisms uncovered along these processes and involving the HOX genes. Finally, we foresee the specific targeting of HOX genes and in general the cell memory gene program in the therapeutic setting of urogenital malignancies due to their upstream location in these stepwise cell processes and their early deregulation in cancer evolution.

AB - Genito-urinary malignancies (prostate, bladder, renal and testicular cancers) rank high among human tumors with an incidence that varies with age and organ involvement. Prostate cancer is the most commonly detected male cancer followed by bladder and kidney cancers, less frequent in women. Testicular cancer, although rare, is the most frequent cancer in males under 35. The majority of oncogenic and tumor suppressor signaling pathways involved with urogenital cancers converge on sets of transcription factors that ultimately control gene expression resulting in tumor formation and metastatic progression. The activity of these transcription factors is modulated by multiple mechanisms spanning from transcriptional regulation, deregulation of the splicing, maturation, export and location of mRNAs, protein synthesis and post-translational modifications. The recent involvement of the epigenitic mechanisms in the generation and the evolution of cancer has produced a great deal of interest. This is related to the possibility that revealing these mechanisms able to regulate the cell memory program (the gene systems polycomb, trithorax and HOX) may generate important biological and therapeutic achievements. The HOX gene network is the only physically and functionally identifiable transcription factor network located in the human genome controlling crucial cellular processes. Here we describe the implication of the HOX genes in the urogenital embryonic development and cancers. We further highlight the mechanisms uncovered along these processes and involving the HOX genes. Finally, we foresee the specific targeting of HOX genes and in general the cell memory gene program in the therapeutic setting of urogenital malignancies due to their upstream location in these stepwise cell processes and their early deregulation in cancer evolution.

KW - Anti-Epigenetic Drugs

KW - Epigenetic therapies

KW - Epigenetics and cancer

KW - HOTAIR

KW - HOTTIP

KW - HOX genes

KW - HOX genes and cell identity

KW - HOX genes and epithelial-mesenchymal interaction

KW - HOX genes and miRNA

KW - HOX genes and ncRNA

KW - HOX genes and uro-genital cancers

KW - HOX/PBX and therapy

KW - HOXC11 and kidney cancer

KW - HOXC4

KW - HOXC5 and HOXC6 and bladder cancer

KW - HOXC6 and prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=80054856200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054856200&partnerID=8YFLogxK

U2 - 10.2174/092986711797535182

DO - 10.2174/092986711797535182

M3 - Article

VL - 18

SP - 4872

EP - 4884

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 32

ER -